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Abstract
Lynch syndrome (LS) individuals are predisposed to a variety of cancers, most commonly colorectal, uterine, urinary
tract, ovarian, small bowel, stomach and biliary tract cancers. The risk of extracolonic manifestations appears to be
highest in MSH2 mutations carriers.
We present a carrier case with a novel MSH2 gene mutation that clearly demonstrates the broad extent of LS
phenotypic expression and highlights several important clinical aspects. Current evidence suggests that colorectal
tumors from LS patients tend to have better prognoses than their sporadic counterparts, however survival benefits
for other cancers encountered in LS are unclear.
In this article we describe a family with a novel protein truncating mutation of c.2388delT in the MSH2 gene,
particularly focusing on one individual carrier affected with multiple primary cancers who is surviving 25 years on.
Our report of multiple primary tumors occurring in the 12-25 years interval might suggest these patients do not
succumb to other extracolonic cancers, provided they are regularly followed-up.
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Introduction
Lynch syndrome (LS), or hereditary nonpolyposis color-
ectal cancer (HNPCC) syndrome, is genetically hetero-
geneous autosomal dominant disease, caused by
mutations in one of at least four mismatch repair
(MMR) genes, most frequently MLH1 or MSH2,w h i c h
account for about 50% and 40% of cases respectively [1].
More than 1000 unique mutations were reported in
each of these genes http://www.insight-group.org. Trun-
cating mutations are the most frequent cause of defi-
cient MMR function, comprising about 68% and 82% of
the types of mutations found in the MLH1 and MSH2
genes respectively [1].
Clinically LS is characterized by a high risk for early-
onset colorectal and endometrial cancers and also a
moderate risk for urinary tract, ovarian, small bowel,
stomach and biliary tract cancers. LS accounts for 2% to
5% of all colorectal cancers [2]. Recognition of LS, lead-
ing to molecular screening for MMR genes in a pro-
band, is currently based on the clinico-familial
Amsterdam II criteria and/or clinico-pathological
Bethesda criteria [3]. Identification of LS causing muta-
tions is important for clinical surveillance in carriers
and genetic testing for at risk relatives.
Considerable variability exists in phenotypic expres-
sion and cancer risk among different gene mutations
carriers. The risk of colon cancer appears to be greater
in carriers of MLH1 vs other MMR genes, but the over-
all risk of all cancers (colonic and extracolonic) com-
bined appears with MSH2 mutations [4]. In MSH2
mutation carriers, relevant genotype-phenotype correla-
tions exist for benign and malignant sebaceous glands
tumors (Muir-Torre syndrome) [2].
It is well known that colorectal tumors from LS
patients tend to have better prognoses than sporadic
colorectal tumors [5] and are associated with distinct
histological characteristics such as tumor-infiltrating
lymphocytes, mucinous/signet-ring differentiation and/
or medullary growth patterns, as well as proximal locali-
zation [6]. However, the survival benefits for other can-
cers in LS are unclear.
There is some inconsistency among cases reported in
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is not classically regarded a LS spectrum tumor [8].
In this article we describe a family with the novel pro-
tein truncating mutation of c.2388delT in the MSH2
gene, focusing particularly on one individual carrier
affected with multiple primary cancers who is surviving
25 years on.
Case report
Currently 63 year old index female patient (III:4) with a
positive colorectal cancer family history was considered
having LS after she presented with a colorectal cancer
in her 47th year (1995), after she already had been diag-
nosed with ovarian cancer at the age of 38 (1986) (Fig-
ure 1). Her personal medical history revealed a total
hysterectomy and bilateral-salpingoophorectomy as a
consequence of treatment for ovarian cancer. The
patient then conformed to Amsterdam II and Bethesda
criteria [3]. For research purposes the patient was
enrolled in a LS screening project and found to be a
carrier of c.2388delT mutation in the 14 exon of MSH2
gene by direct sequencing. This genetic data was
included in a collaborative study report of LS mutation
spectrum from the Baltic countries and Poland [9],
recently referenced in InSiGHT http://www.insight-
group.org, although this mutation and phenotype were
not characterized in more detail at the time.
The patient at the time of diagnosis received standard
treatment in accordance with protocols established at
the Lithuanian Institute of Oncology (briefly outlined in
Table 1). After the rectal cancer diagnosis, she was fol-
lowed-up by 1-2 yearly colonoscopies and clinical exam-
inations as an outpatient.
During a prophylactic mammography performed at
the age of 51, a tumor (3 × 2.5 cm) was localized in the
lower-inner quadrant of the left breast and estrogen
receptor positive infiltrative adenocarcinoma stage II
(T2N0M0) was diagnosed. The patient underwent a left
modified mastectomy, radiotherapy and received
Tamoxifen treatment for 3 years. Chemotherapy was
postponed due to persistent leucopenia and thrombocy-
topenia; the patient agreed to receive only one CMF
(Cyclophosphamide, Methotrexate and 5-FU) regimen
cycle.
After 5 years thereafter, at the age of 56, the patient
arrived with complaints of left sided loin-flank pain. An
enlarged ureter and left hydronephrosis were found and
a moderately differentiated transitional cell carcinoma of
the left ureter was confirmed histopathologically after
partial resection. A left kidney nephrectomy was per-
f o r m e daf e wm o n t h sl a t e r ,s i n c en ok i d n e yf u n c t i o n
was detected by excretional urography. Four years later
an ureter carcinoma metastasis was suspected in the
liver by CT scan, confirmed pathologically after liver
mass biopsy and treated by percutaneous radiofrequency
ablation.
Benign adenoma of the parathyroid gland was diag-
nosed by ultrasound guided biopsy at the age of 57.
At the age of 62, 1 year and 4 months after the last
normal colonoscopy, the patient subsequently developed
a stage II adonocarcinoma of the ascending colon
(visualized endoscopically as a flat 2 cm lesion) and a
right hemicolectomy was performed.
Retrospective immunohistochemical analysis of MMR
proteins in the patients colorectal cancer and urinary
tract carcinoma showed a consistent loss of expression
of MSH2/MSH6 protein complexes.
The niece of the index patient (IV:1, 38 years) was
independently referred to the cancer geneticist in 2010
due to a cancer family history and endometrial cancer
diagnosis at the age of 35 years (Figure 1), meeting both
Amsterdam II and Bethesda criteria. Analysis of mono-
nucleotide BAT25, BAT26 and CAT25 markers [10]
showed instability of all of them and immunohistochem-
istry of MLH1/PMS2 and MSH2/MSH6 proteins indi-
cated the loss of MSH2/MSH6 expression in the
endometrial tumor; direct sequencing of the MSH2 gene
on ABI 3500 (Applied Biosytems) genetic analyzer
revealed the same c.2388delT mutation (p.
Thr796ThrfxX15) in exon 14 (Figure 2). This frame
shifting mutation is predicted to induce a premature
“stop” codon at the downstream 811 amino acid level,
which results in truncated MSH2 protein, presumably
further degraded by nonsense mediated decay (NMD)
[11]. This mutation has not been reported in detail in
the literature.
Neither sister (III:3) nor children (IV:5, IV:6) of the
proband were found to be carriers of the familial dele-
terious MSH2 mutation.
Figure 1 Pedigree of the family with MSH2 c.2388delT
mutation.
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LS can be difficult to diagnose, due to a lack of specific
phenotypic features, and the need for a high level of
clinical suspicion when encountering cardinal LS fea-
tures where extracolonic cancers are integral to the syn-
drome [6]. Our presented carrier case with a novel
MSH2 gene mutation clearly demonstrates the broad
extent of LS phenotypic expression and highlights sev-
eral important clinical aspects.
Firstly, the patient over time presented with five pri-
mary cancers (in different organs) all of them, except
that of breast, typical for the tumor spectrum of LS.
Early-stage ovarian mucinous carcinoma was the first
manifestation of LS spectrum in the proband. The life-
time risk of ovarian cancer in Lynch syndrome is
approximately 10-12% [12], with higher risks (36%)
reported in MSH2 carriers [13]. Recent estimates of age-
specific cumulative cancer risks in Lynch syndrome
families suggest lower than published elsewhere ovarian
cancers risk (24% ovarian cancer risk in MSH2) [14].
MMR-deficient ovarian cancers are biologically and
clinically different from BRCA deficient cancers, the for-
mer overrepresented by non-serous histology types,
early-stage and early-onset disease [12,15].
For LS women, the lifetime risk for endometrial can-
cer (40-80%) is substantially higher than that for color-
ectal cancer (30-60%) [12]; the risk being greater in
MSH2 and MSH6 carriers [16]. We assume that the
increased occurrence of endometrial cancer in the pro-
band III:4 was eliminated by radical hysterectomy per-
formed after the diagnosis of ovarian cancer at the age
of 38, although the other family member IV:1 developed
endometrial cancer at an earlier age (35 years).
The majority of colonic cancers seen in LS patients
have a proximal predilection for site of occurrence and
affect the right colon [6], while rectal cancer (left-sided)
is seen in ~20% of MLH1 and MSH2 carriers [2]. Our
patient presented with firstly left sided then later right
sided colonic cancer. Our patient’s CRCs showed typical
histopathological features of LS: mucinous histology and
lymphocytic infiltration. It was observed that patients
with an initial left-sided CRC developed a metachronous
colon tumor in a statistically significant shorter time
span (medium 12 years) than patients with a first right-
sided CRC (medium 23 years) [2]. Furthermore, one
third of patients having had surgery for a LS-associated
CRC will have a second primary CRC within 10 years of
surgical treatment if the surgery was less than a subtotal
Table 1 The development of multiple primary tumors in patient (individual - index III: 4).
Site of tumor Age at
diagnosis
(years)
Histology Stage
(TNM)
Treatment
Ovary (right) 38 Mucinous cystadenocarcinoma I
(T1N0M0)
Radical hysterectomy+chemotherapy+
radiotherapy (1986)
Rectosigmoid 47 Mucinous adenocarcinoma III
(T3N1M0)
Resection of rectosigmoid part with “end-to-end
anastomosis"+ chemotherapy
Breast (left) 51 Ductal adenocarcinoma II
(T2N0M0)
Mastectomy + radiotherapy (4 fields), tamoxifen (20
mg) 3 years
Ureter (left) 56 Transitional cell ureter carcinoma (G2) II
(T2N0M0)
Resection of ureter + nephroectomy
Adenoma of
parathyroid
57 Ultrasound biopsy
Ureteral metastasis in
liver (S5-6)
60 Transitional cell ureter carcinoma (G2) IV Radiofrequency ablation
Colon (ascending) 61 Adenocarcinoma with partial mucinous
differentiation (G2)
II
(T3N0M0)
Right hemicolectomy
All available pathology and medical reports of cancers occurring in this patient were reviewed.
Figure 2 Sequence analysis of MSH2 gene (Genebank accession
number U04045) with c.2388delT (p.Thr796ThrfsX15) in exon
14.
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right-sided metachronous CRC 14 years after her first
presentation for rectal cancer.
Cancers of the upper urinary tract (renal pelvis/ureter)
o c c u rm o r ef r e q u e n t l yi nL S ,w i t hal i f e t i m er i s ko f4 %
compared with < 1% in the general population [17], and
a r em o r ec o m m o ni nMSH2 mutation carriers, reaching
up to 9% for women and 20% for men who are such
mutation carriers [18,19]. Upper urinary tract cancers
are rarely diagnosed before the age of 40 years [2]. In
our proband carcinoma of the ureter was the most
aggressive cancer type, unfortunately metastasizing to
the liver - a poor prognostic factor.
Breast cancer is not generally regarded as a tumor
specific to LS, and lifetime risks are not increased in LS
patients, although MMR may have effects on the pro-
gression of breast tumors [7,16]. Of note, is that the
occurrence of both ovarian and breast cancer in our
patient led to an erroneous assumption of the involve-
ment of BRCA mutations by one physician. We have
additionally screened (by high resolution melting analy-
sis) BRCA1/2 genes for five common mutations in
Lithuania (4 in BRCA1 and 1 in BRCA2). On the other
hand, mucinous ovarian cancer is not found to be asso-
ciated with BRCA1/2 genes [12,15]. About half of breast
cancers arising in MMR gene mutation carriers have
MMR proteins deficiencies and thus breast tissue sam-
ples may be used to improve identification of patients at
risk [7,20]. Unfortunatelly, we were unable to perform
additional MMR immunohistochemical staining because
of the unavailability of necessary material.
We were unable to confirm neither the history nor
find appearance of sebaceous tumors (Muirr-Torre var-
iant), which can be seen in MSH2 or MLH1 carriers.
Additionally, the most striking feature of our case
report is that our MSH2 mutation carrier, who experi-
enced multiple cancers, is surviving 25 years after her
first cancer diagnosis. Improved survival with CRC,
compared to unselected sporadic CRC cases, has been
consistently reported in LS patients [21,22], although
this feature is also common for non-syndromic MSI
instable CRCs. The data for other extracolonic LS can-
cers are scarce, and one study found no survival rate dif-
ferences between ovarian cancer patients with LS and
those with sporadic ovarian cancers [23]. Our survival
data for CRC strongly supports increased survival in LS/
MMR defective cases and sharply contrasts with pre-
vious observations for ovarian cancer. A very recent
study found that the risk of dying from (diagnosed)
ovarian cancer in germline MMR deficient patients is
about 2% [24]. Our results are in line with the notion
that MMR genes may predispose to a biologically differ-
ent type of ovarian cancer than BRCA1/2 or in the gen-
eral population, characterized by early stage disease at
presentation and favorable prognosis [24]. After the
MSH2 mutation confirmation in 1998 (at the age of 50),
our case was regarded consistent with LS and therefore
12 years of survival data were collected prospectively.
Given the absence of published survival data for extra-
colonic cancers in LS patients, our report of multiple
primary tumors occurring in the 12-25 years interval
might suggest that these patients do not succumb to
other extracolonic cancers, provided they are on regu-
larly follow-up.
Currently, only colonoscopic surveillance is proven to
reduce the incidence of mortality from CRC and so is
recommended every 1-2 years beginning at the age of
20-25 years [5]. Our case demonstrates that an optimal
colonoscopy interval lies closer to 1 year, since a second
asymptomatic stage II CRC was diagnosed only 1 year
and 4 months after the last normal colonoscopy.
The other LS patient (IV:1) was recommended to be
followed up by annual colonoscopy, abdominal ultra-
sound, urinalysis, gastroduodenoscopy and H. pylori
detection and eradication. However, effective surveil-
lance protocols for other extracolonic cancers need still
to be identified [19].
In conclusion, prolonged survival in our case of a car-
rier of the novel MSH2 mutation affected by multiple
cancers, raises current challenges in the management of
individuals with LS. Obviously, from a single case we
can not unequivocally draw conclusions about multiple
tumor phenotype correlations with the particular muta-
tion, without having to admit possible influences of
modifier genes [25], which may also have effects on
tumor spectra to be encountered and survival rates of
probands. Additionally, host immune system responses
might be enchanced to MMR-deficient tumors [26].
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